{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:35:12Z","timestamp":1791171312111,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1462,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/jto.0b013e3182307e1f","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T03:44:26Z","timestamp":1320291866000},"page":"2018-2026","source":"Crossref","is-referenced-by-count":55,"title":["Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin\/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients"],"prefix":"10.1016","volume":"6","author":[{"given":"Vienna","family":"Ludovini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Floriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Pistola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Meacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Garavaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Tofanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Flacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Siggillino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Tonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3182307e1f_bib1","author":"NCCN"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrg1229","article-title":"Pharmacogenetics goes genomic","volume":"4","author":"Goldstein","year":"2003","journal-title":"Nat Rev Genet"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.ge.29.120195.000441","article-title":"DNA repair in humans","volume":"29","author":"Sancar","year":"1995","journal-title":"Annu Rev Genet"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib4","first-page":"555","article-title":"Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene","volume":"16","author":"Yu","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib5","first-page":"162","article-title":"ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy","volume":"1","author":"Park","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib6","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","article-title":"ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer","volume":"11","author":"Viguier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","article-title":"Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy","volume":"44","author":"Ryu","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib9","first-page":"8654","article-title":"Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp\/Asp genotype","volume":"61","author":"Seker","year":"2001","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib10","first-page":"1354","article-title":"Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients","volume":"61","author":"Spitz","year":"2001","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib11","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","article-title":"Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","article-title":"Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients","volume":"17","author":"De las Pe\u00f1as","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLC.2003.n.004","article-title":"Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine\/cisplatin-treated advanced non-small-cell lung cancer patients","volume":"4","author":"Camps","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/carcin\/22.9.1437","article-title":"XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects","volume":"22","author":"Matullo","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/carcin\/23.2.295","article-title":"Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD\/ERCC2 genotypes","volume":"23","author":"Qiao","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib16","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1093\/carcin\/bgh264","article-title":"Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer","volume":"25","author":"Popanda","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/mutage\/geg008","article-title":"TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis","volume":"18","author":"Matakidou","year":"2003","journal-title":"Mutagenesis"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib18","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","article-title":"Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo","volume":"23","author":"Sullivan","year":"2004","journal-title":"Oncogene"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib19","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1158\/1078-0432.CCR-04-1547","article-title":"Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs","volume":"11","author":"Vikhanskaya","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lungcan.2004.07.043","article-title":"Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance","volume":"47","author":"Bepler","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib21","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-05-1969","article-title":"Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics","volume":"12","author":"Gilbert","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib22","first-page":"421","article-title":"Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.","volume":"26","author":"Kirch","year":"1998","journal-title":"Exp Hematol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00008571-200301000-00005","article-title":"A functional single-nucleotide polymorphism in human cytidine deaminase gene contributing to ara-C sensitivity","volume":"13","author":"Yue","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0006-2952(95)02402-6","article-title":"Regulation of phosphorylation of deoxycytidine and 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine); effects of cytidine 5\u2032-triphosphate and uridine 5\u2032-triphosphate in relation to chemosensitivity for 2\u2032,2\u2032-difluorodeoxycytidine","volume":"51","author":"Ruiz van Haperen","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0006-2952(98)00318-9","article-title":"Decreased resistance to gemcitabine (2\u2032,2\u2032-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase","volume":"57","author":"Bergman","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002800050832","article-title":"Drug resistance to 5-aza-2\u2032-deoxycytidine, 2\u2032,2\u2032-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells","volume":"42","author":"Eliopoulos","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib27","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1158\/1078-0432.CCR-04-1497","article-title":"Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin","volume":"11","author":"Yonemori","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","article-title":"Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism","volume":"25","author":"Sugiyama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours","volume":"92","author":"Arbuck","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","article-title":"Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in Gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"14","author":"Tibaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib31","first-page":"1340","article-title":"Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine","volume":"24","author":"Neff","year":"1996","journal-title":"Exp Hematol"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00439-006-0142-0","article-title":"Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter","volume":"119","author":"Fitzgerald","year":"2006","journal-title":"Hum Genet"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib33","first-page":"5457","article-title":"Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD","volume":"62","author":"Aloyz","year":"2002","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib34","first-page":"1354","article-title":"Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients","volume":"61","author":"Spitz","year":"2001","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/carcin\/23.4.599","article-title":"The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk","volume":"23","author":"Hou","year":"2002","journal-title":"Carcinogenesis (Lond)"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib36","first-page":"8654","article-title":"A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3182307e1f_bib37","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","article-title":"XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy","volume":"22","author":"Gurubhagavatula","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415317263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T18:27:38Z","timestamp":1543429658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415317263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1556086415317263"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3182307e1f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}